1 / 3

Nintedanib

Boc Sciences offers 656247-17-5 Nintedanib (Intedanib) in bulk, please inquire us to get a quote for 656247-17-5 Nintedanib (Intedanib).<br>https://www.bocsci.com/nintedanib-cas-656247-17-5-item-262244.html

bocsci2018
Download Presentation

Nintedanib

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nintedanib (Intedanib) - CAS 656247-17-5 Catalog number: B0084-262244 Nintedanib is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM. It is used for the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). Please be kindly noted that our product can only be used for research to orgnizations or companies and we don't cooperate with personal buyers. Category Inhibitor Targets VEGFR FGFR SARS-CoV-2 Molecular Formula C31H33N5O4 Molecular Weight 539.62 Ordering Information Catalo g Numbe r Siz e Pric e Stoc k Quantity B0084- 262244 500 mg $279In stock 0 Bulk Inquiry Add to cart Chemical Information Category Inhibitor

  2. Molecular Formula C31H33N5O4 Molecular Weight 539.62 Specification Properties QC Data Reference Reading     Purity ≥98% Related CAS 656247-18-6 (esylate) 656247-17-5 (free base) Appearance Light Green to Light Yellow Solid Synonyms Vargatef; BIBF-1120; BIBF 1120; BIBF1120; Intedanib Solubility Soluble to 9.66 mg/L in water. Clinical Trial Information NCT Number Title Condition Or Disease Phase Start Date Sponsor Status NCT00706628A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer Prostatic Neoplasms Phase 2 March 2006 Boehringer Ingelheim Completed NCT00710762A Randomised Placebo- Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Ovarian Neoplasms Phase 2 March 2006 Boehringer Ingelheim Completed

  3. Cancer NCT00715403A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120 Neoplasms Phase 1 October 2004 Boehringer Ingelheim Completed NCT00730821Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors Neoplasms Phase 1 January 2007 Boehringer Ingelheim Completed NCT00806819Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC Carcinoma, Non- Small-Cell Lung Phase 3 December 2008 Boehringer Ingelheim Completed Preparing Stock Solutions ConcentrationVolumeMass 1 mg 5 mg 10 mg 1 mM 1.8532 mL 9.2658 mL 18.5316 mL 5 mM 0.3706 mL 1.8532 mL 3.7063 mL 10 mM 0.1853 mL 0.9266 mL 1.8532 mL 50 mM - - - https://www.bocsci.com/nintedanib-cas-656247-17-5-item-262244.html

More Related